Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy

Chunhui Li,Tongren Yang,Yuhua Weng,Mengjie Zhang,Deyao Zhao,Shuai Guo,Bo Hu,Wanxuan Shao,Xiaoxia Wang,Abid Hussain,Xing-Jie Liang,Yuanyu Huang
DOI: https://doi.org/10.1016/j.bioactmat.2021.05.051
IF: 18.9
2022-03-01
Bioactive Materials
Abstract:Ionizable iLP181 (pKa 6.43) enabled efficient cellular entry and endosomal escape.The psgPLK1 plasmid was constructed with optimized PLK1-targeting sgRNA.iLP181/psgPLK1 triggered efficacious and long-time gene editing <em>in vitro</em> and <em>in vivo.</em>iLP181/psgPLK1 achieved superior tumor suppression, without inducing side effects.CRISPR/Cas9-based gene editing has emerged as a powerful biotechnological tool, that relies on Cas9 protein and single guided RNA (sgRNA) to edit target DNA. However, the lack of safe and efficient delivery carrier is one of the crucial factors restricting its clinical transformation. Here, we report an ionizable lipid nanoparticle (iLP181, p<em>K</em>a = 6.43) based on iLY1809 lipid enabling robust gene editing <em>in vitro</em> and <em>in vivo</em>. The iLP181 effectively encapsulate psgPLK1, the best-performing plasmid expressing for both Cas9 protein and sgRNA targeting Polo-like kinase 1 (PLK1). The iLP181/psgPLK1 nanoformulation showed uniformity in size, regular nanostructure and nearly neutral zeta potential at pH 7.4. The nanoformulation effectively triggered editing of PLK1 gene with more than 30% efficiency in HepG2-Luc cells. iLP181/psgPLK1 significantly accumulated in the tumor for more than 5 days after a single intravenous injection. In addition, it also achieved excellent tumor growth suppression compared to other nucleic acid modalities such as siRNA, without inducing adverse effects to the main organs including the liver and kidneys. This study not only provides a clinically-applicable lipid nanocarrier for delivering CRISPR/Cas system (even other bioactive molecules), but also constitutes a potential cancer treatment regimen base on DNA editing of oncogenes.<span class="display"><span><ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S2452199X21002723-ga1_lrg.jpg"><span class="anchor-text">Download : <span class="download-link-title">Download high-res image (447KB)</span></span></a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S2452199X21002723-ga1.jpg"><span class="anchor-text">Download : <span class="download-link-title">Download full-size image</span></span></a></li></ol></span></span>
engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?